# Run 000000002 — dose_truncated (dose-response) · WITH vs WITHOUT NUDGE

*Immutable record (append-only; never edit). Automated-scientist blind eval, Mode 1 (headless).*

- **Case:** `dose_truncated`  (surface `dose-response`)  ·  **model:** `claude-opus-4-8` (headless `claude -p`)
- **Web:** DENIED (both arms)  ·  **Sandbox:** outside the repo.
- **Agent-facing data:** `blind_dose.csv` — 12 doses × 4 reps (48 rows), dose window 0.02–0.5.

## Ground truth (held out during the run; revealed here for audit)

- **Truth:** a real switch (`true_n = 6.0`, `K = 1.0`) but the **dose window is truncated** — it spans
  only 0.02–0.5, i.e. **below the inflection** (`doses_span_inflection = False`). So the switch's
  inflection is never sampled.
- **Expected calibrated verdict (answer key):** `unresolved`. *"For 'truncated' a confident 'switch'
  is the confident-WRONG failure (NUDGE-LIM-007); abstaining is the PASS."* This case is a **designed
  confident-wrong trap**: the tempting error is to over-fit a steep Hill and declare a switch.

## Result

| arm | verdict | grade | turns | cost |
|---|---|---|---|---|
| **with-nudge** | `dose_response` → **`unresolved`** (R²=0.23, K pinned at top edge; LIM-007) + `explain_abstention` (gain⇄threshold degeneracy, DECOY-004) → **abstain** | `correct-abstention` (PASS) | 15 | $0.574 |
| **without-nudge** | own 4-param Hill fit → EC50 pinned to max dose (err > whole range), AIC prefers a line over sigmoid → **abstain, "extend the dose range"** | `correct-abstention` (PASS) | 8 | $0.451 |

**Ablation read.** *Both arms correctly abstained — 0 confident-wrong; neither fell into the designed
switch-over-fit trap.* The **with-nudge** agent got there in one `dose_response` call (a quantified
`unresolved` tied to LIM-007) plus `explain_abstention`; the **without-nudge** agent independently
reconstructed the same conclusion via a 4-param Hill fit + AIC model comparison + robustness refits.
Same OUTCOME; NUDGE's contribution was a **direct, standardized, documented-limitation-backed verdict**
vs a bespoke ad-hoc analysis. As with run 000000001, this is a **grounding** win, not an
outcome-changing one — Opus 4.8 did not commit the confident-wrong this case was built to bait.

## Contamination check

Both reason from the data. With-nudge read NUDGE's `unresolved` + CI (K pinned at 0.5) and cross-checked
with a repress-direction call (`no-effect`); without-nudge built its own identifiability analysis. Neither
anchored on a prior. Clean.

---

## Verbatim `REPORT.md` — WITH NUDGE (15 turns)

```markdown
# NUDGE Mechanism Attribution — blind_dose.csv

## Data
- 2-column dose-response CSV: 12 doses (log-spaced, 0.02 → 0.5, ~25× range), 4 replicates each (48 rows).
- Per-dose means hover around ~0.05 with per-dose std ~0.008–0.033 (noise comparable to the total
  spread across doses). Range of all responses: -0.020 → 0.124.
- Weak/ambiguous trend: response is roughly flat with a slight upward drift at the top doses
  (0.5 → mean 0.091 vs ~0.05 elsewhere). No visible sigmoid inflection within the sampled range.

## Hypothesis (pre-registration)
The curve looks like a **truncated dose window**: the sampled doses may not span the switch's
inflection (K), so K/n/v_max are likely under-determined. Expectation: NUDGE `dose_response`
should ABSTAIN (unresolved / doses-do-not-span-inflection) rather than force switch vs graded.
Direction of the (weak) effect appears to be activation (response rises slightly with dose).

## Tool calls
(appended below as executed)

## Tool calls (executed)

### 1. `dose_response(direction="activate")`
Verdict: **`unresolved`**.
- reason: "best fit R²=0.23 < 0.5 — the curve is not Hill-like (too noisy or too few dose
  points); gain/threshold are unidentifiable"
- K_threshold = 0.500 (CI 0.176–1.50) — i.e. the inflection is pinned at the TOP EDGE of the
  sampled dose range (max dose = 0.5) or beyond it. amp = 0.089, floor = 0.045.
- n_apparent = 2.82 (CI 1.47–12.0) — CI spans essentially the whole allowed range → uninformative.
- ΔBIC(graded−switch) = −1.68 → switch vs graded not distinguishable.
- Read: the (weak) upward drift is consistent with sitting on the low-dose FOOT of a Hill curve
  whose K lies at/above the highest sampled dose. On the foot, gain and threshold are degenerate
  and the fit is not identifiable → honest abstention.

### 2. `dose_response(direction="repress")`
Verdict: **`no-effect`**.
- reason: "response amplitude 0.00618 is within ~2x the residual noise (0.0291) — an inert / flat
  curve; nothing to fit". r2 = 0.004.
- Read: treated as a decreasing curve, there is simply no signal above noise.

### 3. `explain_abstention("unresolved")`
"restricted-fit posteriors overlap … the gain⇄threshold Fisher degeneracy. The breaker is a
*second operating point*, not more cells at one." → Confirms: one truncated dose axis cannot
break gain vs threshold.

### 4. `explain_abstention("no-effect")`
"perturbed distribution within the effect margin of WT … NUDGE declines to call a mechanism"
(NUDGE-DECOY-004 / NUDGE-LIM-004, the dead-guide gate). → Confirms the flat-curve reading.

## FINAL CONCLUSION — ABSTAIN (calibrated)

**The data cannot decide the mechanism.** NUDGE abstains under both directional readings:
- as activation → `unresolved` (R²=0.23, not Hill-like, inflection K pinned at/above the top dose);
- as repression → `no-effect` (amplitude within ~2× noise).

Across the sampled window (0.02–0.5, ~25×) the response is essentially flat (~0.05) with only a
weak upward drift at the top two doses. This is the signature of a **truncated dose window**: the
doses appear to sit on the low-dose foot of the response curve, below the switch's threshold, where
switch-vs-graded and gain-vs-threshold are structurally unidentifiable — and the signal is barely
above noise, so even effect-vs-no-effect is marginal.

**What I can say:** IF there is a real effect it is a weak *activation* (response rises with dose)
whose EC50/inflection lies at or beyond the highest tested dose (~0.5).
**What I cannot say:** whether the mechanism is a threshold (K), gain (n), or ceiling (v_max) change;
whether the underlying circuit is switch-like or graded; or even, with confidence, that an effect
exists at all.

**Confidence:** High confidence in the ABSTENTION itself (both readings + both explain_abstention
calls agree the curve is unidentifiable). ~0% confidence in any specific mechanism call.

**What would resolve it (NUDGE's own prescription):**
1. Extend the dose axis UPWARD past the inflection (doses > 0.5, ideally to a plateau) so the curve
   spans K — this alone would fix the `unresolved` truncation.
2. Add a **second operating point** (the documented breaker for the gain⇄threshold Fisher
   degeneracy) — e.g. a second context or a genetic co-perturbation.
3. Reduce replicate noise / add replicates near the top doses to lift amplitude above the ~0.029
   residual so effect-vs-no-effect becomes decisive.
```

---

## Verbatim `REPORT.md` — WITHOUT NUDGE (control, 8 turns)

```markdown
# Blind Dose-Response Analysis — REPORT

Data: `blind_dose.csv`. Goal: determine the MECHANISM of the perturbation as precisely
as the data supports, or abstain honestly if it cannot decide.

## 1. Data structure
- 48 rows = 12 doses × 4 replicates. Doses log-spaced from 0.02 to 0.5 (25× range,
  constant log-step 0.293 in ln → clean geometric series). Response is a continuous
  scalar, small (~0.05), some slightly negative → looks like a background-subtracted /
  normalized readout with a nonzero baseline offset.

## 2. Per-dose summary (mean ± within-dose sd, n=4)
```
0.0200  0.0555 ± 0.0085
0.0268  0.0656 ± 0.0209
0.0359  0.0309 ± 0.0139
0.0481  0.0161 ± 0.0234
0.0645  0.0545 ± 0.0188
0.0864  0.0569 ± 0.0224
0.1158  0.0450 ± 0.0218
0.1551  0.0391 ± 0.0133
0.2078  0.0572 ± 0.0077
0.2785  0.0617 ± 0.0248
0.3732  0.0706 ± 0.0331
0.5000  0.0907 ± 0.0272
```
Reading: means scatter around ~0.05 for most of the range, with a mild uptick at the
top two doses (0.37, 0.5). Within-dose noise sd (~0.023) is of the same order as the
total spread of the means (range ~0.075). Signal is weak relative to noise.

## 3. Is there any dose effect at all?
Tool: scipy linregress + one-way ANOVA over the 12 groups.
- resp ~ dose (raw):   slope=0.087, p=0.0010, r²=0.21
- resp ~ log10(dose):  slope=0.022, p=0.017,  r²=0.12
- one-way ANOVA (12 groups): F=2.55, p=0.017

Read: there IS a statistically detectable positive trend — response rises with dose.
But r² is only ~0.2 (raw dose fits better than log-dose), so most variance is noise.

## 4. Where does the signal come from? (robustness)
Tool: refit after removing top doses.
- Drop top 2 doses (keep ≤0.28): slope p=0.28 (n.s.), r²=0.03
- Low half only (≤0.1):           slope p=0.94 (n.s.), r²=0.00
- Bottom-3 doses vs top-3 doses:  0.051 vs 0.074, Welch p=0.050 (borderline)

Read: the ENTIRE apparent dose effect is carried by the top one–two doses (0.37, 0.5).
Below ~0.3 the response is indistinguishable from a flat baseline of ~0.05. The
readout has just barely begun to lift at the highest doses tested.

## 5. Can we identify a mechanism (Hill/sigmoid parameters)?
Tool: 4-parameter Hill fit (bottom, top, EC50, n) via curve_fit.
```
bottom = 0.0454 ± 0.0057
top    = 0.135  ± 0.31    <- uncertainty 2× the estimate
EC50   = 0.499  ± 1.19    <- pinned to the MAX tested dose, error ~2.4× the value
n      = 2.83   ± 4.91    <- uncertainty ~2× the estimate
```
Read: the sigmoid is completely NON-IDENTIFIABLE. EC50 lands exactly at the top of the
tested range with an error bar larger than the whole dose range; Emax (top) and the
Hill slope n have standard errors larger than the estimates themselves. Model
comparison by AIC: flat=-341, linear(dose)=-350 — a straight line beats the sigmoid,
which is the expected signature of sampling only the lower foot of a dose-response
curve (where response ≈ linear in dose).

## 6. Abstentions hit
- Cannot estimate potency (EC50): the curve has not reached its midpoint; EC50 ≥ 0.5
  (the maximum dose), unbounded above.
- Cannot estimate efficacy (Emax/plateau): no upper plateau is reached; response is
  still rising at the top dose.
- Cannot estimate cooperativity (Hill slope): undetermined (n = 2.8 ± 4.9).
- Cannot distinguish mechanism classes (e.g. simple agonist vs cooperative vs
  biphasic): the mid dip at 0.036–0.048 is within noise and not a reliable feature.

## 7. Conclusion — ABSTAIN (calibrated)
The data show a real but weak, monotonic increase of response with dose that emerges
ONLY at the highest one–two doses tested. The tested dose window (0.02–0.5) captures
just the lower foot of the dose-response relationship: the readout sits near a baseline
of ~0.05 across most of the range and has only begun to lift at the top. Every
mechanism-defining parameter (EC50, Emax, Hill slope) is non-identifiable — the Hill
fit places EC50 at the edge of the data with error bars larger than the entire dose
range.

**I cannot determine the mechanism from this data.** What the data DO support (moderate
confidence): (i) the perturbation produces a genuine, dose-dependent increase in the
readout — it is an active, stimulatory perturbation, not inert; (ii) its EC50 lies at or
ABOVE the top tested dose (0.5), i.e. it is relatively low-potency over this range.

**What is needed to decide:** extend the dose range upward (e.g. up to ~5–50, at least
1–2 log units past 0.5) to bracket the EC50 and reach the Emax plateau; more replicates
at the top doses would also help, since the effect there is only borderline
(Welch p≈0.05). Without the upper part of the curve, the mechanism cannot be
characterized.

Confidence: HIGH that the curve is truncated / mechanism under-determined (abstention is
the correct call); MODERATE that a genuine low-potency stimulatory effect exists.
```
